Ann Buikema-Wiarda, MD
Ophthalmology · Warsaw, INNPI 1538146246
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,960 of the $12,951 with a category attached, or 76.9%. Alcon accounts for 62.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $3,861 and has fallen 54.6% since, to $1,753 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $81.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$8K
- Rxsight Inc$2K
- Regeneron Healthcare Solutions, Inc.$739
- Glaukos Corporation$717
- AbbVie$442
- Sight Sciences, Inc.$329
- plus $625 from 9 others
What the payments were for
- Travel & lodging$2,87122%
- Food & beverage$9,96077%
- Gifts$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 73 | $8,128 |
| Rxsight Inc | 22 | $1,971 |
| Regeneron Healthcare Solutions, Inc. | 11 | $739 |
| Glaukos Corporation | 12 | $717 |
| AbbVie(2 entities) | 15 | $442 |
| Sight Sciences, Inc. | 6 | $329 |
| Genentech USA, Inc. | 10 | $254 |
| Novartis | 1 | $124 |
| GSK | 1 | $100 |
| Omeros Corporation | 2 | $35 |
| Biotissue Holdings Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| NEW World Medical,inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$3,015
- Centurion$2,726
- ARGOS$2,109
- RXSIGHT CONTACT LENS$1,220
- RXSIGHT INJECTOR CARTRIDGE$1,220
- RXSIGHT INJECTOR HANDPIECE$1,220
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,220
- LIGHT ADJUSTABLE LENS (LAL)$846
- LenSx$546
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$513
- ORA$506
- DAILIES$492
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$374
- EYLEA$372
- EYLEA HD$244
- iDoseTR$175
- Clareon PanOptix Pro$145
- ReSTOR$142
- AcrySof IQ VIVITY$142
- Luxor$141
How this compares
$12,951 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 42 | $28,043 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $13,423 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $7,963 |
| Latanoprost | 824 | $7,272 |
| Prednisolone Acetate | 186 | $7,208 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 42 | $7,123 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 257 | $3,755 |
| Travoprost | 31 | $3,310 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,838 |
| Brimonidine Tartrate | 217 | $2,780 |
| Diclofenac Sodium | 123 | $2,292 |
| Dorzolamide Hcl | 72 | $1,635 |
| Timolol Maleate | 122 | $983 |
| MoxifloxacinMoxifloxacin Hcl | 13 | $275 |
| Ciprofloxacin Hcl | 26 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $442 | $41,46673 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $16 | $7,96314 claims |
| AlconSimbrinza | $8,128 | $2,83814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Warsaw
- Bruce GrossnickleWarsaw$16K
- Christopher KnightWarsaw$7K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.